Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV

Anaïs Corma-Gómez 1,2,3, Marta Fernández-Fuertes 1,2,3, Estefanía García 1, Ana Fuentes-López 3,4,5, Cristina Gómez-Ayerbe 6, Antonio Rivero-Juárez 3,7,8,9, Carmen Domínguez 1, Marta Santos 1,4,5, Laura Viñuela 3,4,5, Rosario Palacios 6, Luis M. Real 2,3,10, Antonio Rivero 3,7,8,9, Juan Macías 1,2,3,11,*, Juan A. Pineda 1,2,3,11, Federico García 3,4,5

1) Unit of Infectious Diseases and Microbiology, Hospital Universitario Virgen de Valme, Sevilla, Spain
2) Instituto de Biomedicina de Sevilla, Sevilla, Spain
3) Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Madrid, Spain
4) Clinical Microbiology Unit, Hospital Universitario Clínic San Cecilio, Granada, Spain
5) Instituto de Investigacion Biosanitaria Ibs.Granada, Granada, Spain
6) Unit of Infectious Diseases, Hospital Universitario Virgen de la Victoria, Málaga, Spain
7) Unit of Infectious Diseases, Hospital Universitario Reina Sofia, Córdoba, Spain
8) Instituto Maimonides de Investigación Biomédica de Córdoba, Córdoba, Spain
9) University of Córdoba, Córdoba, Spain
10) Department of Surgery, Biochemistry and Immunology, School of Medicine, University of Málaga, Málaga, Spain
11) Medicine Department, University of Sevilla, Sevilla, Spain

Objectives: The aim of this study was to assess the immunogenicity of SARS-CoV-2 available vaccines among people living with HIV (PLWH) after a complete vaccination scheme, and determine predictors of seroconversion.

Methods: This multicentre prospective cohort study included 420 PLWH who had received a standard immunization, either with mRNA or adenoviral-vectored COVID-19 vaccines. Antibody response was evaluated within 1 to 2 months after the last dose of the vaccine with a quantitative determination of antitrimeric spike protein-specific IgG antibodies and IgG neutralizing antibodies.

Results: Overall, 384 of 420 PLWH (91%) showed antibody response to vaccination. Seroconversion was observed in 308 of 326 individuals with cluster of differentiation 4 (CD4) counts >200 cells/mm3 (95%), 55 of 61 PLWH with 200 to 349 cells/mm3 (90%), and 21 of 33 PLWH with CD4 counts <200 cells/mm3 (64%; p < 0.001). The median log10 IgG neutralization levels were 2.4 IU/mL (Q1–Q3, 1.0–3.1) among PLWH with CD4 counts <200 cells/mm3, 3.1 IU/mL (Q1–Q3, 2.8–3.4) for the 200 to 349 cells/mm3 group, and 3.1 IU/mL (Q1–Q3, 2.7–3.4) for PLWH with CD4 counts >350 cells/mm3. The median log10 IgG neutralization levels were 2.8 IU/mL (Q1–Q3, 2.0–3.5) among PLWH with CD4 counts <200 cells/mm3 (95%), 3.1 IU/mL (Q1–Q3, 2.8–3.4) for the 200 to 349 cells/mm3 group, and 3.1 IU/mL (Q1–Q3, 2.7–3.4) for PLWH with CD4 counts >350 cells/mm3 (p < 0.001). The median log10 IgG neutralization levels were 2.4 IU/mL (Q1–Q3, 1.0–3.1) among PLWH with CD4 counts <200 cells/mm3, 3.1 IU/mL (Q1–Q3, 2.8–3.4) for the 200 to 349 cells/mm3 group, and 3.1 IU/mL (Q1–Q3, 2.7–3.4) for PLWH with CD4 counts >350 cells/mm3 (p < 0.001). In the multivariate analysis, CD4 counts >350 cells/mm3 (OR: 7.10; 95% CI, 1.91–26.46; p = 0.004) and receiving mRNA-vectored COVID-19 vaccines (OR: 8.19; 95% CI, 3.24–20.70; p < 0.001) were independently associated with a higher probability of response to vaccination.

Discussion: HIV-related immunosuppression impairs the antibody response to SARS-CoV-2 vaccines. Specific vaccination schemes should be urgently tailored in this setting, particularly in patients with CD4 cell counts <200 cells/µL. Adenoviral-vectored vaccines should be avoided in PLWH whenever possible.

Anaïs Corma-Gómez, Clin Microbiol Infect 2022;28:1492
© 2022 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
(PLWH) [1]. Despite the availability of several vaccines, the pandemic remains difficult to control. Currently available SARS-CoV-2 vaccines show high efficacy in terms of prevention of severe COVID-19, hospitalization, and COVID-19-related death [2–4]. However, the efficacy of these vaccines in PLWH has not been entirely well-established to date. Only a few clinical trials have included PLWH, mostly with high clustering of differentiation 4 (CD4) cell counts and suppressed HIV viremia achieved with antiretroviral therapy (ART) [3,4]. More recently, preliminary observational studies have suggested that, in well-controlled PLWH, immunization rates after mRNA vaccines delivery were similar to those observed in the general population [5,6]. However, the results of these studies may be limited because of their low sample size and, especially, because PLWH with low CD4 cell counts were not included. Therefore, the available data are insufficient and may not be accurate.

Likewise, there is no available information on how specific factors may affect the performance of vaccination in PLWH. Despite ART, the immune dysfunction associated with HIV infection may not be completely reversed [7]. For this reason, SARS-CoV-2 vaccination might result in immune responses of lesser magnitude and/or persistence among PLWH, as seen in the setting of other vaccine-eligible diseases, especially in individuals with severe immunosuppression [8]. In addition, the type of vaccine and the presence of specific comorbidities might preclude the development of a protective immunological response. Hence, there is an urgent need to characterize the immune response and correlates of vaccine efficacy in PLWH, and more specifically in those with a more advanced immune deficiency.

Thus, the aim of this study was to assess the immunogenicity of available SARS-CoV-2 vaccines among PLWH after a complete vaccination scheme, and determine factors associated with seroconversion.

Methods

Study design and patients

This multicentre prospective cohort study of PLWH was conducted at the units of infectious diseases of three university hospitals in Southern Spain from January to December 2021. PLWH were invited to participate if they met the following inclusion criteria: Age > 18 years and complete immunization scheme, either with mRNA or adenovirus-vectored COVID-19 vaccines. Blood samples were obtained from all participants between 4 and 8 weeks after the last dose of the COVID-19 vaccine. Patients with documented prior SARS-CoV-2 natural infection diagnosed by PCR, antigen detection, or serology were excluded.

Vaccination schemes

Immunization was carried out according to the national recommendations in force [9]. Vaccination schemes were considered complete when patients received either two doses of the Pfizer-BioNTech mRNA vaccine (BNT162b2), Moderna (mRNA-1273 Spikevax), or adenovirus-vectored Oxford-AstraZeneca vaccine (ChAdOx1 nCoV-19; AZD1222), or one dose of the adenovirus-vectored COVID-19 Janssen vaccine (Ad26.COV2.S).

Outcomes and definitions

The main outcome of this study was the presence of specific IgG antibodies against the spike protein (anti-S) of SARS-CoV-2 ≥ 33.8 binding antibody units per mL (BAU/mL) [10]. Seroconversion was defined as the detection of anti-S levels above this cut-off point. All patients who did not reach this anti-S level after a complete immunization scheme were considered nonresponders to vaccination. Additionally, levels of anti-S and IgG neutralization antibodies within the spike protein encoded by vaccines after vaccination were determined. PLWH were stratified according to CD4 cell counts, evaluated within 3 months before vaccination, in three groups: <200 cells/m³, 200 to 349 cells/m³, and ≥350 cells/m³. Comorbidities were evaluated from patients’ electronic clinical records at each centre. Chronic kidney disease was defined as glomerular filtration rate <35 mL/min/1.73 m² for ≥3 months, irrespective of cause.

Laboratory procedures

To rule out natural infection, all patients were tested every 6 months since the onset of the COVID-19 pandemic for SARS-CoV-2 total antibodies (including IgG) against the nucleocapsid protein (anti-N) by electrochemiluminescence immunoassay (ELECSYST Anti-SARS-CoV-2; Roche Diagnostic International) as routine clinical follow up. Measurement of anti-N was also performed at the time of vaccination response assessment. Titres of SARS-CoV-2 spike binding antibodies against the subunits S1 and S2 of the virus spike protein were measured with chemiluminescent immunoassay automated equipment (LIASON SARS-CoV-2 IgG kit; DiaSorin, Saluggia, Italy) on a LIASON XL analyzer in accordance with the manufacturer’s instructions. The immunogenicity results are reported as an international standard unit (BAU/mL for binding assay formats).

Specificity and sensitivity were 100% (95% CI, 95%–100%) and 91% (95% CI, 79%–96%) using the cut-off point provided by the manufacturer [10]. Serum IgG neutralizing antibodies were analyzed using a COVID-19 Spike Quantitative Vircila IgG Monotest (VIRCELL, S.L., Granada, Spain). The assay is an indirect chemiluminescent immunoassay to test IgG antibodies in SARS-CoV-2 Spike, used as a surrogate marker of neutralization, with a specificity and sensitivity of 100% (95% CI, 96%–100%) 99% (95% CI, 92%–100%) against a neutralization assay [11].

Statistical analysis

First, descriptive analyses were performed. Continuous variables were expressed as median (Q1–Q3) and categorical variables as frequencies (percentage). The rate of COVID-19 vaccine responders was calculated by dividing the number of responders by the total number of PLWH included in the study. Continuous variables were categorized by the median value or clinically relevant cut-off points. Anti-S and neutralization IgG level values were log transformed for the analysis. Frequencies were compared with the χ² or Fisher’s test when there was at least one cell with an expected frequency lower than five. The Mann–Whitney U test was used to compare continuous variables. A one-way analysis of variance was used for comparisons among three or more groups. In addition, a post hoc analysis was performed for pairwise group comparisons. A multiple-comparisons correction was performed with the Bonferroni or Tamhane method. The correlation between anti-S and neutralization IgG was assessed with a Spearman correlation analysis. Differences were considered statistically significant for p values ≤ 0.05.

A multivariable binary logistic regression was used to assess risk factors associated with no response to COVID-19 vaccination. Baseline variables that were significantly different among the CD4 cell counts strata, along with factors associated with no response to COVID-19 vaccination, in the bivariable analysis with a p value < 0.2 were included in the multivariable model, along with age and sex.
Data are number (%) of participants. CD4, cluster of differentiation 4.

Table 1
Characteristics of the study population (N = 420)

| Parameter, n (%) | CD4 cell counts <200 cells/mm³ (n = 61) | CD4 cell counts 200-349 cells/mm³ (n = 33) | CD4 cell counts ≥350 cells/mm³ (n = 61) | Overall (N = 420) | Univariate p value |
|----------------|----------------------------------------|----------------------------------------|----------------------------------------|-----------------|-----------------|
| Male sex       | 28 (85)                                 | 49 (80)                                 | 266 (82)                                | 343 (82)        | 0.862           |
| Age, y         | 56 (51–61)                              | 56 (52–62)                              | 55 (48–60)                              | 55 (49–60)      | 0.466           |
| Injection drug use | 15 (47)                               | 37 (61)                                 | 107 (33)                                | 159 (38)        | <0.001          |
| Cirrhosis      | 6 (18)                                  | 17 (28)                                 | 24 (7)                                  | 47 (11)         | <0.001          |
| Chronic kidney disease | 4 (12)                      | 1 (2)                                   | 5 (2)                                   | 10 (2)          | <0.001          |
| Immunosuppressive therapy | 1 (3)                      | 3 (5)                                   | 9 (3)                                   | 13 (3)          | 0.672           |
| Charlson index | 4 (2–7)                                 | 2 (1–4)                                 | 2 (0–3)                                 | 2 (1–3)         | <0.001          |
| CDC clinical category A | 4 (14)                                | 28 (48)                                 | 196 (62)                                | 228 (57)        | <0.001          |
| Nadir CD4 cell counts, cells/mm³ | 30 (9–71)                         | 127 (47–253)                            | 270 (112–421)                           | 223 (70–376)    | <0.001          |
| Plasma HIV-RNA <50 c/mL | 23 (70)                          | 52 (87)                                 | 289 (93)                                | 362 (87)        | <0.001          |

Data are number (%) of participants. CD4, cluster of differentiation 4.

Table 2
Distribution of SARS-CoV-2 vaccines by CD4 cell counts (N = 420)

| Parameter, n (%) | CD4 cell counts <200 cells/mm³ (n = 33) | CD4 cell counts 200-349 cells/mm³ (n = 61) | CD4 cell counts ≥350 cells/mm³ (n = 61) | Overall (N = 420) | p value |
|----------------|----------------------------------------|----------------------------------------|----------------------------------------|-----------------|---------|
| mRNA vaccines  | 28 (90)                                 | 43 (74)                                 | 239 (79)                                | 310 (79)        | 0.198   |
| Adenovirus vaccines | 3 (10)                       | 15 (26)                                 | 63 (21)                                 | 81 (21)         |         |

Data are number (%) of participants. CD4, cluster of differentiation 4.

Ethics

This study was conducted according to the Helsinki declaration, and approved by the ethics committee of the Hospital Universitario Virgen de Valme. All patients gave written informed consent before being recruited in this study.

Results

Characteristics of the study population

Supplementary Fig. 1 depicts the study flowchart. A total of 420 PLWH were included in this study. The main features of the study population are displayed in Table 1. All participants were receiving ART at the time of SARS-CoV-2 vaccination, and 362 PLWH (86%) had a plasma HIV-RNA load of <50 cp/mL. The median CD4 cell count was 586 cells/mm³ (Q1–Q3, 380–786). Thirty-three PLWH (8%) showed CD4 cell counts <200 cells/mm³, and 114 PLWH (27%) had CD4 cell counts <350 cells/mm³. PLWH with CD4 cell counts <200 cells/mm³ more frequently had chronic kidney disease, lower nadir CD4 cell counts, and detectable HIV viremia (Table 1).

SARS-CoV-2 vaccination and antibody response in PLWH

Most patients were immunized with mRNA vaccines (Table 2). The proportion of individuals who received SARS-CoV-2 mRNA vaccination was higher among PLWH with CD4 cell counts <200 cells/mm³ than in patients with CD4 cell counts above this cutoff point (Table 2). Overall, 351 PLWH (91.2%) showed seroconversion after a complete vaccination scheme. When accounting for type of vaccine, a greater proportion of PLWH seroconverted after receiving mRNA vaccination compared with those who were immunized with the adenovirus-vectorized COVID-19 vaccine (Table 3). Seroconversion was more common in individuals with CD4 cell count ≥350 cells/mm³, followed by patients with cell counts of 200 to 349 cells/mm³, than among PLWH with CD4 cell counts <200 cells/mm³ (Fig. 1).

The level of serum antibody reached was associated with CD4 cell counts (Fig. 2). Hence, the group with the lowest CD4 cell counts had reduced IgG anti-S levels compared with those in the other two groups (median log10 IgG anti-S: 1.9 BAU/mL (Q1–Q3, 0.7–3.1) vs. 2.8 BAU/mL (Q1–Q3, 2.2–3.1; p = 0.041) and 2.7 BAU/mL (Q1–Q3, 2.3–3.1; p = 0.008) for the 200 to 349 cells/mm³ and ≥350 cells/mm³ groups, respectively; Fig. 2A). Likewise, neutralization IgG levels were lower among PLWH with severe immunosuppression (median log10 neutralization IgG: 2.4 IU/mL (Q1–Q3, 1.0–3.1) vs. 3.1 IU/mL (Q1–Q3, 2.8–3.4; p = 0.013) and 3.1 IU/mL (Q1–Q3, 2.7–3.4; p = 0.003) for the 200 to 349 cells/mm³ and ≥350 cells/mm³ groups, respectively; Fig. 2B). A high correlation was observed between anti-S and neutralization IgG levels (Spearman's rho: 0.844; p < 0.001).

Predictors of seroconversion after SARS-CoV-2 vaccination among PLWH

In the bivariate analysis, predictors of seroconversion after SARS-CoV-2 immunization were CDC clinical category, nadir CD4 cell counts, CD4 cell counts, and plasma HIV RNA before vaccination, as well as type of vaccine (Table 3). In the multivariate analysis, age, type of vaccine, and CD4 cell counts before vaccination were predictors of seroconversion after SARS-CoV-2 complete vaccination scheme (Table 3).

Discussion

This study suggests that, among PLWH with low CD4 cell counts, COVID-19 vaccine humoral responses is reduced with standard immunization schemes. In contrast, among individuals with CD4...
Table 3
Predictors of antibody response to vaccination among people living with HIV (N = 420)

| Variables                          | Categories                        | Response to vaccination, n (%) | Bivariable p-value | OR (95% CI) Multivariable p-value |
|------------------------------------|-----------------------------------|-------------------------------|--------------------|-----------------------------------|
| Sex                                | Male; female                      | 316 (92); 68 (88)             | 0.280              | Ref; 0.64 (0.24–1.75)             | 0.383 |
| Age, years (< 55; ≥ 55)            |                                   | 178 (90); 206 (93)           | 0.290              | 1.04 (1.00–1.08)                  | 0.040 |
| HIV infection way                  | Injection; noninjection drug user  | 144 (91); 240 (92)           | 0.622              | 1.47 (0.55–3.90); Ref             | 0.441 |
| CDC clinical category              | A, B, or C                        | 220 (97); 154 (88)           | <0.001             | 2.56 (0.98–6.63); Ref             | 0.054 |
| Nadir CD4 cell counts (cells/mm³)  | <200; ≥ 200                       | 143 (88); 188 (97)           | 0.001              | —                                 | —     |
| Charlson index (≤ 2; > 2)          |                                   | 170 (93); 214 (90)           | 0.345              | —                                 | —     |
| Cirrhosis                          | No; yes                           | 343 (89); 41 (87)            | 0.270              | 1.59 (0.43–5.86); Ref             | 0.489 |
| Chronic kidney disease             | No; yes                           | 375 (98); 9 (90)             | 0.596              | —                                 | —     |
| Immunosuppressive therapy          | No; yes                           | 373 (92); 11 (85)            | 0.297              | —                                 | —     |
| CD4 cell counts, cells/mm³         | <200; 200–349; ≥ 350               | 21 (64); 55 (90); 308 (95)   | <0.001             | Ref; 3.94 (0.84–18.53); 7.10 (1.91–26.46) | 0.084; 0.004 |
| Plasma HIV-RNA, c/mL               | ≤ 50; ≥ 50                        | 336 (92); 33 (81)            | 0.019              | 0.98 (0.27–3.52); Ref             | 0.973 |
| Vaccine                            | mRNA; adenovirus                  | 292 (94); 63 (78)            | <0.001             | 8.19 (3.24–20.70); Ref            | <0.001 |

Table shows patient characteristics associated with a greater probability of seroconverting after a complete immunization scheme against SARS-CoV-2. For the bivariate analysis, continuous variables were categorized according to the median value or using clinically significant cut-off points. Variables associated with the main endpoint in the bivariate analysis with p < 0.05, along with baseline characteristics that showed significant differential distribution among CD4 strata, were entered in a multivariate analysis, and a logistic binary regression model was conducted. Age was entered as a continuous variable, and all other parameters were entered as categorical variables. The model was built using an automatic procedure. The validity of the final model was assessed by estimating goodness of fit with the Hosmer–Lemeshow test. Results are expressed as OR and their 95% CI. In total, six variables, along with age and sex, were included in the final model. The Hosmer–Lemeshow test was used for goodness of fit for logistic regression with p = 0.676. Ref, reference.

a) Available for 357 patients.

b) The parameter nadir CD4 cell count was not entered in the model to avoid overfitting. Instead, CD4 cell count at the time of vaccination was selected, because this parameter is a strong predictor of response in the setting of other vaccines in people living with HIV.

c) Not entered in the model because of the small number of cases.

d) Per 1 year increase (included as continuous variables in multivariate model).

Fig. 1. Proportion of people living with HIV who seroconvert after COVID vaccination, by cluster of differentiation 4+ cell count (N = 420).

Fig. 2. Levels of A) IgG antibodies against the spike protein by cluster of differentiation 4+ cell count (N = 420); and B) neutralization IgG by cluster of differentiation 4+ cell count (N = 420).
The rates of seroconversion after COVID-19 immunization are high. Additionally, vaccination elicited robust humoral response in this subset. Finally, mRNA vaccines seem to be more immunogenic than adenovirus-vectored COVID-19 vaccines, also in PLWH.

Characterizing the response to SARS-CoV-2 vaccination among PLWH is essential to design effective vaccination programs. PLWH have an elevated risk of severe COVID-19 disease, which is related to CD4 cell counts and HIV viral load [12]. For this reason, PLWH, and particularly those with severe immunosuppression, are prioritized for SARS-CoV-2 vaccination [9]. Despite efficient virological suppression and immune recovery with normalization of CD4 cell counts on ART, immune dysfunction, chronic HIV-related inflammation, and T-cell senescence may persist [7]. Particularly, among PLWH, low CD4 cell counts are commonly associated with a poorer response to vaccination against other preventable diseases [8], and immunization schemes must be boosted in this population to achieve immune protection. To date, information on COVID-19 vaccination response in this subset is scant. Several studies have examined the ability of the Pfizer-BNT162b2 mRNA or ChAdOx1 nCoV-19 vaccine to elicit an immune response to SARS-CoV-2 in PLWH. Most studies concluded that well-controlled PLWH mount similar immune responses as HIV-negative controls individuals [5,6,13–15].

Nevertheless, there is some controversy regarding the effect of CD4 cell counts on the response induced by those vaccines. One study found a similar anti-SARS-CoV-2 binding antibody response in PLWH with CD4 counts <300 cells/μL compared with HIV-negative individuals [15], but other studies showed a considerably weaker response among PLWH with some degree of immunosuppression [16–20]. The main limitation of these studies was the small number of participants with low CD4 cell counts. In the present study, the frequency of nonseroconverters was slightly higher among PLWH with CD4 cell counts <350 cells/mm³ and dramatically increased among those with CD4 cell counts <200 cells/mm³. In addition, levels of anti-S and neutralization IgG were significantly lower in the group of PLWH with CD4 <200 cells/mm³. Conversely, no significant differences were found when comparing individuals with 200 to 350 cells/mm³ with patients with ≥350 cells/mm³. Our results are in agreement with those of previous studies of PLWH with high CD4 cell counts. In addition, we provide data on the poorer response to vaccination of PLWH with CD4 cell counts <200 cells/mm³.

The effect of HIV status on the protection mediated by the adenovirus-vectored vaccine is not fully known. Despite promising data from a phase 2/3 clinical trial [13], results should be interpreted with caution because the sample size was small and PLWH with severe immunosuppression were excluded from the study. In the present work, PLWH who received adenovirus-vectored vaccines were less likely to seroconvert after a full immunization scheme. Again, because of the observational study design, we must be cautious in the interpretation of these data. Nonetheless, a recent meta-analysis revealed that, among the general population, BNT162b2 and mRNA-1273 vaccines were associated with the highest efficacy to prevent symptomatic COVID-19 compared with other vaccines [21].

There is a substantial body of evidence for a strong humoral and cellular response after SARS-CoV-2 vaccination that may persist over many months [22], which also seems to occur in well-controlled PLWH [23]. Besides, high antibody levels were recently demonstrated to correlate with strengthened vaccine efficacy and a decreased risk of COVID-19, mainly mediated by neutralizing antibodies [24]. In that study, IgG anti-S and neutralization IgG levels were also strongly correlated. In the present work, a high correlation was also observed between anti-S and neutralization IgG levels. Consequently, in many viral diseases [25], antibody determination could be an accessible biomarker to assess individual risks. Thus, such determinations could easily allow for the identification of individuals who may require tailored immunization strategies to achieve long-term protection. These individuals might benefit from receiving additional vaccine doses, which has demonstrated in a preliminary study to strongly boost humoral response in PLWH with advanced disease [26]. In addition, antibody determination may be helpful to establish immunization priorities, particularly in subsets with supply shortage of COVID-19 vaccine.

This study has some limitations. First, because of its observational nature, there might be a risk of unbalanced groups for comparison. However, after adjusting for variables associated with seroconversion and those different among CD4 cell counts strata, CD4 cell counts were independent predictors of seroconversion after vaccination. Second, cellular immune response was not assessed. For SARS-CoV-2, as well as other respiratory viruses, coordination between humoral and cellular responses is pivotal to control and clear SARS-CoV-2 [22]. In this sense, antibody titres might be underestimating the potential breadth of the immune
response to SARS-CoV-2 [27]. Nevertheless, in PLWH, a correlation has been observed between the CD4/CD8 ratio and the magnitude of T-cell responses against SARS-CoV-2 [28]. Additionally, a preliminary study has shown that cellular-mediated response after COVID-19 immunization in PLWH with CD4 cell counts <200 cells/mm³ is poorer than in PLWH with CD4 cell counts >500 cells/mm³ [23]. Finally, the size of the group with CD4 cell counts <200 cells/mm³ was small. However, this is fortunately the current scenario among PLWH under ART [29]. In this sense, to our knowledge, this is the first study to include a high number of PLWH with current low CD4 cell counts who were vaccinated with available mRNA or adenoviral-vectorized COVID-19 vaccines. Additionally, prior SARS-CoV-2 infection was ruled out by testing the entire cohort every 6 months for anti-N. Given that PLWH have a lower probability of CoV-2 infection was ruled out by testing the entire cohort every 6 months for anti-N. Given that PLWH have a lower probability of showing detectable anti-N than people without HIV infection after COVID-19 [30], performing a single anti-N test may lead to an underestimation of prior COVID-19. These are strengths of this study.

Conclusions

Available COVID-19 vaccines elicit robust humoral responses in well-controlled PLWH, especially those who have received mRNA vaccines. However, individuals with CD4 cell counts <200 cells/mm³ are less likely to respond to a complete immunization scheme, which might put them at a higher risk of a COVID-19 breakthrough infection and worse clinical outcomes. This finding supports the urgency of developing improved SARS–CoV-2 vaccination strategies for PLWH who are poorly immunosuppressed. PLWH with low CD4 cell counts could benefit from monitoring seroconversion and antibody titres to tailor vaccination schemes.

Research ethics statement

This study was conducted according to the Helsinki declaration, and approved by the ethics committee of the Hospital Universitario Virgen de Valme. All patients gave written informed consent before being recruited in this study.

Transparency declaration

The authors report no conflict of interest. This work was supported, in part, by the Spanish Network for AIDS Investigation (www.red.es/redes/inicio; RD16/0025/0040) as part of the Nacional de Salud Carlos III. Anaïs Corma-Gómez received a research extension grant from the Programa de la Actividad Investigadora en las Unidades Clínicas del Servicio Andaluz de Salud 2021, grant number A1-0060-2021. Marta Santos received a Río Hortega grant from the Ministerio de Ciencia, Promoción y Universidades of Spain (INT20-00028).

Author contributions

Conceptualization by ACG, LMR, JM, JAP, and FG. Methodology by ACG, LMR, JM, JAP, and FG. Formal analysis by ACG, LMR, JM, and JAP. Investigation by ACG, MFF, EG, AFL, LV, and FG. Resources by ACG, MFF, EG, AFL, LV, CGA, ARJ, CD, MS, RP, AR, LMR, JM, JAP, and FG. Data curation by ACG and MFF. Writing of the original draft by ACG and JM. Review and editing by ACG, MFF, EG, AFL, LV, CGA, ARJ, CD, MS, RP, AR, LMR, JM, JAP, and FG. Visualization by ACG, MFF, and JM. Supervision by JM, JAP, LMR, and FG. Project administration by ACG, MFF, and JM. Funding acquisition by JM, JAP, and FG.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2022.05.018.

References

[1] Geretti AM, Stockdale AJ, Kolly SH, Ceviç M, Collins S, Waters L, et al. Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): a prospective observational study. Clin Infect Dis 2021;73:e2095–106. https://doi.org/10.1093/cid/ciaa1695.
[2] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603–15. https://doi.org/10.1097/NEJMoa2000202.
[3] Baden LR, EI Sahly HM, Essink B, Koroff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–16. https://doi.org/10.1056/NEJMoa2020410.
[4] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99–111. https://doi.org/10.1016/S0140-6736(20)32661-1.
[5] Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect 2021;27:1851–5. https://doi.org/10.1016/j.cmi.2021.07.031.
[6] Woldemeskel BA, Karaha AH, Gariass CC, Beck EJ, Wang KH, Laeyendecker O, et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV). Clin Infect Dis 2022;74:1268–70. https://doi.org/10.1093/cid/ciab648.
[7] Paiardini M, Müller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev 2013;254:78–92. https://doi.org/10.1111/imr.12079.
[8] Kerneis S, Launay O, Turbelin C, Bateaux F, Hanslik T, Boelle PY. Long-term immunologic responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis 2014;58:1130–9. https://doi.org/10.1093/cid/cit937.
[9] de Sanidad Ministerio. Estrategia de vacunación. https://www.mscbs.gob.es/profesionales/saludpublica/alertasalertas/Actual/nCoV/vacunaCovid19.htm. [Accessed 22 January 2022].
[10] Tré-Hardy M, Wilmet A, Beukinga I, Dognin JM, Douxfils J, Blaurock L. Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody. Clin Chem Lab Med 2020;58:1357–64. https://doi.org/10.1515/cclm-2020-0594.

Roche Diagnostics GmbH. Elecsys anti-SARS-CoV-2 S assay. 2021. [https://www.roche.com/professionals/saludpublica/cdc/latex/SARS-COV-2-ELECSYS.html].
[11] Sun J, Patel RC, Zheng Q, Madhira V, Olex AL, Islam JY, et al. COVID-19 disease severity among people with HIV infection or solid organ transplant in the United States: a nationally-representative, multicenter, observational cohort study. medRxiv. In press. https://doi.org/10.1101/2021.07.26.21261028.
[12] Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV 2021;8:e474–85. https://doi.org/10.1016/S2352-3018(21)00103-X.
[13] Rebby JA, Boyarsky BJ, Werbel WA, Bailey JR, Karaha AH, Gariass L, Wang JM, et al. Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV. AIDS 2021;35:1872–4. https://doi.org/10.1097/QAD.0000000000002945.
[14] Bergman P, Blennow O, Hansson L, Miettinen S, Nowak P, Chen P, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EbioMedicine 2021;74:103705. https://doi.org/10.1016/j.ebiom.2021.103705.
[15] Nault L, Marchitto L, Goyette G, Tremblay-Sher D, Fortin C, Martel-Laferrière V, et al. COVID-19 vaccine immunogenicity in people living with HIV-1. Vaccine 2022;40:3633–7. https://doi.org/10.1016/j.vaccine.2022.04.090.
[17] Heftdal LD, Knudsen AD, Hamm SR, Hansen CB, Möller DL, Pries-Heje M, et al. Humoral response to two doses of BNT162b2 vaccination in people with HIV. J Intern Med 2022;291:513–8. https://doi.org/10.1111/joim.13419.

[18] Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A et al. Immunogenicity of mRNA vaccination against SARS-CoV-2 in persons living with HIV (PLWHs) with low CD4 count or previous AIDS. Presented at: European AIDS Clinical Society 18th European AIDS Conference. London, UK; October 27–30, 2021.

[19] Touizer E, Alrubayyi A, Rees-Spear C, Fisher-Pearson N, Griffith SA, Muir L, et al. Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV. Lancet HIV 2021;8:e317–8. https://doi.org/10.1016/S2352-3018(21)00099-0.

[20] Hassold N, Brichler S, Ouedraogo E, Leclerc D, Carroue S, Gater Y, et al. Impaired antibody response to COVID-19 vaccination in advanced HIV infection. AIDS 2022;36:F1–5. https://doi.org/10.1097/QAD.0000000000003166.

[21] Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep 2021;11:22777. https://doi.org/10.1038/s41598-021-02321-z.

[22] Cicalini S, Vergori A, Cozzi-Lepri A, Meschi S, Bordoni V, Lanini S, et al. Durability of SARS-CoV-2 mRNA vaccine immune response in PLWH with advanced disease. CROI 2022;2:291.

[23] Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022;375:43–50. https://doi.org/10.1126/science.abm3425.

[24] Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17:1055—65. https://doi.org/10.1128/CVI.00131-10.

[25] Reynolds CJ, Swadling L, Gibbons JM, Pade C, Jensen MP, Diniz MO, et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci Immunol 2020;5:eabf3698. https://doi.org/10.1126/sciimmunol.abf3698.

[26] Cicalini S, Vergori A, Cozzi-Lepri A, Matusali G, Bordoni V, Lanini S, et al. Immunogenicity and reactogenicity to CVOID-19 mRNA vaccine additional dose in PLWH. CROI 2022;2:291.

[27] Berenguer J, Díez C, Martín-Vicente M, Micó MJ, Piqué-Elías MJ, García-Fraile LJ, et al. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV research network cohort. Clin Microbiol Infect 2021;27:1678–84. https://doi.org/10.1016/j.cmi.2021.06.023.

[28] Macías J, Fernández-Fuertes M, Oliver N, Corma-Gómez A, Real LM, Pineda JA. Lower probability of persistence of total anti-SARS-CoV-2 antibodies after COVID-19 among people living with HIV. Clin Microbiol Infect 2022;28:755–6. https://doi.org/10.1016/j.cmi.2022.01.028.